SG187941A1 - Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) - Google Patents

Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) Download PDF

Info

Publication number
SG187941A1
SG187941A1 SG2013013453A SG2013013453A SG187941A1 SG 187941 A1 SG187941 A1 SG 187941A1 SG 2013013453 A SG2013013453 A SG 2013013453A SG 2013013453 A SG2013013453 A SG 2013013453A SG 187941 A1 SG187941 A1 SG 187941A1
Authority
SG
Singapore
Prior art keywords
matrix
transdermal therapeutic
gestodene
active
ingredient
Prior art date
Application number
SG2013013453A
Other languages
English (en)
Inventor
Stefan Bracht
Ildiko Terebesi
Thomas Langguth
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44653285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG187941(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of SG187941A1 publication Critical patent/SG187941A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG2013013453A 2010-09-06 2011-09-02 Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) SG187941A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010040299A DE102010040299A1 (de) 2010-09-06 2010-09-06 Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
PCT/EP2011/065204 WO2012031985A1 (de) 2010-09-06 2011-09-02 Transdermale therapeutische systeme mit kristallisationsinhibierender schutzfolie (release liner)

Publications (1)

Publication Number Publication Date
SG187941A1 true SG187941A1 (en) 2013-04-30

Family

ID=44653285

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013013453A SG187941A1 (en) 2010-09-06 2011-09-02 Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
SG10201506927TA SG10201506927TA (en) 2010-09-06 2011-09-02 Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201506927TA SG10201506927TA (en) 2010-09-06 2011-09-02 Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)

Country Status (33)

Country Link
US (2) US8557279B2 (enExample)
EP (1) EP2613771A1 (enExample)
JP (2) JP6104800B2 (enExample)
KR (1) KR20130114127A (enExample)
CN (1) CN103079549B (enExample)
AP (1) AP3586A (enExample)
AR (1) AR082907A1 (enExample)
AU (1) AU2011298892B2 (enExample)
BR (1) BR112013005305A2 (enExample)
CA (1) CA2810103C (enExample)
CL (1) CL2013000636A1 (enExample)
CO (1) CO6690753A2 (enExample)
CR (1) CR20130098A (enExample)
CU (1) CU24172B1 (enExample)
DE (1) DE102010040299A1 (enExample)
DO (1) DOP2013000053A (enExample)
EA (1) EA032575B1 (enExample)
EC (1) ECSP13012477A (enExample)
GT (1) GT201300062A (enExample)
IL (2) IL224980A (enExample)
MA (1) MA34581B1 (enExample)
MX (1) MX2013002602A (enExample)
MY (1) MY162768A (enExample)
NZ (1) NZ607630A (enExample)
PE (2) PE20180198A1 (enExample)
PH (1) PH12013500429A1 (enExample)
SG (2) SG187941A1 (enExample)
TN (1) TN2013000087A1 (enExample)
TW (1) TWI576245B (enExample)
UA (1) UA110217C2 (enExample)
UY (1) UY33590A (enExample)
WO (1) WO2012031985A1 (enExample)
ZA (1) ZA201301389B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH674618A5 (enExample) * 1987-04-02 1990-06-29 Ciba Geigy Ag
EP0573133A1 (de) * 1988-10-27 1993-12-08 Schering Aktiengesellschaft Mittel zur transdermalen Applikation das Gestoden enthält
JPH06502419A (ja) 1990-10-29 1994-03-17 アルザ・コーポレーション 経皮避妊製剤、方法及びデバイス
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4210711A1 (de) 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
BR0015802B1 (pt) 1999-11-24 2014-04-29 Agile Therapeutics Inc Sistema de administração de contraceptivo transdérmico, e, método para produzir um sistema de administração de contraceptivo transdérmico
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
US20020106402A1 (en) 2000-12-05 2002-08-08 Hartwig Rod Lawson Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
EP1216699A1 (de) 2000-12-21 2002-06-26 Schering Aktiengesellschaft Transdermalsystem enthaltend ein hochpotentes Gestagen
US20030165547A1 (en) * 2001-05-18 2003-09-04 Elisabeth Picard-Lesboueyries Cosmetic uses of 3beta-acetoxy-7-oxo-DHEA
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
KR100704825B1 (ko) * 2003-02-21 2007-04-09 바이엘 쉐링 파마 악티엔게젤샤프트 Ｕｖ 안정성 경피 치료 플라스터
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
CA2549916C (en) * 2003-12-12 2013-09-17 Schering Aktiengesellschaft Transdermal delivery system of hormones without penetration enhancers
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
MX2007004315A (es) * 2004-10-08 2008-03-11 Noven Pharma Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo.
DE102004062182B4 (de) 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
KR20110082142A (ko) * 2008-10-06 2011-07-18 밀란 테크놀로지즈 인코포레이티드 비정질 로티고틴 경피 시스템

Also Published As

Publication number Publication date
BR112013005305A2 (pt) 2016-08-16
JP2013536828A (ja) 2013-09-26
AP2013006787A0 (en) 2013-04-30
JP6104800B2 (ja) 2017-03-29
EA032575B1 (ru) 2019-06-28
GT201300062A (es) 2015-01-16
EP2613771A1 (de) 2013-07-17
CN103079549B (zh) 2016-11-02
UY33590A (es) 2011-10-31
PE20180198A1 (es) 2018-01-26
ZA201301389B (en) 2021-05-26
EA201390246A1 (ru) 2013-09-30
ECSP13012477A (es) 2013-04-30
NZ607630A (en) 2015-02-27
CR20130098A (es) 2013-05-15
KR20130114127A (ko) 2013-10-16
AR082907A1 (es) 2013-01-16
TW201217165A (en) 2012-05-01
US20120082714A1 (en) 2012-04-05
DE102010040299A1 (de) 2012-03-08
US8557279B2 (en) 2013-10-15
CN103079549A (zh) 2013-05-01
IL224980A (en) 2017-07-31
PE20131138A1 (es) 2013-10-26
DOP2013000053A (es) 2013-07-15
AU2011298892A1 (en) 2013-03-28
US20140018751A1 (en) 2014-01-16
CL2013000636A1 (es) 2013-09-13
MX2013002602A (es) 2013-04-08
UA110217C2 (en) 2015-12-10
CO6690753A2 (es) 2013-06-17
CU24172B1 (es) 2016-04-25
AU2011298892B2 (en) 2015-03-12
MY162768A (en) 2017-07-14
SG10201506927TA (en) 2015-10-29
CA2810103A1 (en) 2012-03-15
PH12013500429A1 (en) 2019-10-07
CA2810103C (en) 2019-06-18
JP2016216500A (ja) 2016-12-22
CU20130031A7 (es) 2013-05-31
US9060955B2 (en) 2015-06-23
WO2012031985A1 (de) 2012-03-15
IL251124A0 (en) 2017-04-30
TWI576245B (zh) 2017-04-01
AP3586A (en) 2016-02-10
MA34581B1 (fr) 2013-10-02
TN2013000087A1 (en) 2014-06-25
IL251124B (en) 2020-07-30

Similar Documents

Publication Publication Date Title
CA2161004C (en) Active ingredient patch
US5676968A (en) Transdermal therapeutic systems with crystallization inhibitors
US5554381A (en) Low flux matrix system for delivering potent drugs transdermally
AU712692B2 (en) Transdermal therapeutic systems containing crystallization inhibitors
US8668925B2 (en) Transdermal delivery of hormones without the need of penetration enhancers
Gupta et al. Transdermal delivery: product and patent update
US20070264319A1 (en) Transdermal Antiemesis Delivery System, Method and Composition Therefor
CN113613637B (zh) 含有阿戈美拉汀的经皮治疗系统
WO2021098791A1 (zh) 一种含有美金刚的透皮贴剂
US9060955B2 (en) Transdermal therapeutic system with crystallization-inhibiting protective film (release liner)
WO2020092990A1 (en) Pharmaceutical compositions and methods of making a patch formulation for transdermal delivery
AU2015203180B2 (en) Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
Kharia et al. Overview of transdermal medicated patches with its research updates in preceding years.
HK1184696B (zh) 具有结晶抑制保护膜的透皮治疗系统
HK1184696A (en) Transdermal therapeutic systems with crystallization-inhibiting protective film
TW201311452A (zh) 具抑制結晶保護膜（離型襯墊）之經皮治療系統
EP2613772B1 (en) Low-dose transdermal patches with high drug release